Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00129168]
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) [clinicaltrials:NCT00129168]
Bio2RDF identifier
NCT00129168
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00129168
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Chemotherapy drugs use ...... acute myeloid
leukemia.
brief title [clinicaltrials_vocabulary:brief-title]
Zosuquidar in Combination With ...... d Acute Myeloid Leukemia (AML)
completion date [clinicaltrials_vocabulary:completion-date]
2008-03-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Purpose:
Phase I ...... newly diagnosed AML patients.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-08-09T00:00:00Z
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Chemotherapy
Cytarabine
Daunorubicin
Leukemia, Myeloid
Zosuquidar
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2008-03-28T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00129168
official title [clinicaltrials_vocabulary:official-title]
An Open-Label, Phase I/II, Mul ...... agnosed Acute Myeloid Leukemia
org study id [clinicaltrials_vocabulary:org-study-id]
KAN-979-01
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2008-03-01T00:00:00Z
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2005-08-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2008-03-01T00:00:00Z
identifier
clinicaltrials:NCT00129168
title
Zosuquidar in Combination With ...... d Acute Myeloid Leukemia (AML)
@en
type
label
Zosuquidar in Combination With ...... ) [clinicaltrials:NCT00129168]
@en